What is SKINVIVE by JUVÉDERM used for now after FDA approval?

SKINVIVE is now FDA-cleared for improvement of neck appearance in addition to its original indications for chin and jawline contouring. It's a smooth, cohesive hyaluronic acid filler designed for subtle volumization and skin quality improvement in thin-skinned areas prone to laxity.

How is SKINVIVE different from traditional dermal fillers?

SKINVIVE is a smooth, cohesive HA filler optimized for subtle volumization and skin quality improvement, rather than deep line correction like traditional cross-linked fillers. This makes it better suited for delicate areas like the neck where a softer approach is needed.

Do medspa practices need new training or equipment to offer SKINVIVE for neck treatment?

No. Since SKINVIVE is an existing product with a new indication, practices already stocking it for chin and jawline work require no additional training or device acquisition to offer neck treatments.

How does the Allē rebate program affect SKINVIVE pricing for practices?

SKINVIVE margin economics are tied to Allergan's Allē rebate program and per-syringe cost. Practices should verify their current loyalty terms with Allergan to confirm rebate levels and ensure pricing aligns with their profit targets.

Why is the neck a good treatment area for SKINVIVE?

The neck is thin-skinned and prone to laxity, making it an ideal candidate for SKINVIVE's mechanism of subtle volumization and skin quality improvement rather than aggressive volumizing fillers.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

Allergan Wins FDA Nod for SKINVIVE by JUVÉDERM for Neck — New Indication, Familiar Economics

The FDA cleared SKINVIVE by JUVÉDERM for neck appearance improvement, expanding the HA filler's approved indications.

By Evan at Inside MedSpa · Jul 7, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Allergan Aesthetics received FDA approval for SKINVIVE by JUVÉDERM for improvement of neck appearance. The approval expands the indication beyond the product's original clearance for chin and jawline contouring, opening a new treatment area for practices already stocking the product.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/allergan-skinvive-juvéderm-neck-fda-approval/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Allergan Wins FDA Nod for SKINVIVE by JUVÉDERM for Neck — New Indication, Familiar Economics

Share

Discussion

Leave a comment

By the time it's news, it's too late.